Literature DB >> 10233980

RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection.

E Vigne1, I Mahfouz, J F Dedieu, A Brie, M Perricaudet, P Yeh.   

Abstract

Hypervariable region 5 (HVR5) is a hydrophilic, serotypically nonconserved loop of the hexon monomer which extrudes from the adenovirus (Ad) capsid. We have replaced the HVR5 sequence of Ad5 with that of heterologous peptides and studied their effects on virus viability and peptide accessibility. A poliovirus model epitope was first inserted in a series of nine "isogenic" viruses that differed in their flanking spacers. Whereas virus productivity was not profoundly altered by any of these modifications, immunoprecipitation experiments under nondenaturing conditions demonstrated that epitope recognition by its cognate monoclonal antibody (C3 MAb) was strongly linker dependent and correlated perfectly with the ability of C3 MAb to inhibit transgene delivery and expression. An alphav-specific ligand (DCRGDCF) was then inserted in a suitable linker context to investigate whether hexon-modified capsids would enhance the transduction of cells displaying limiting amounts of the virus attachment receptors. Interestingly, although hexon has never been implicated in Ad entry, the modified virus significantly increased the transduction of human vascular smooth muscle cells in vitro. Competition experiments with 293 cells saturated with recombinant knob further indicated that the hexon-modified virus could use an additional, knob-independent pathway for entry. We concluded that genetic engineering of the Ad5 hexon monomer constitutes a novel and feasible approach to equip the virus with additional targeting ligands.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10233980      PMCID: PMC112562     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Antipeptide antisera define neutralizing epitopes on the adenovirus hexon.

Authors:  C I Toogood; J Crompton; R T Hay
Journal:  J Gen Virol       Date:  1992-06       Impact factor: 3.891

2.  Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism.

Authors:  V N Krasnykh; G V Mikheeva; J T Douglas; D T Curiel
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

3.  Recombinational construction in Escherichia coli of infectious adenoviral genomes.

Authors:  J Crouzet; L Naudin; C Orsini; E Vigne; L Ferrero; A Le Roux; P Benoit; M Latta; C Torrent; D Branellec; P Denèfle; J F Mayaux; M Perricaudet; P Yeh
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

4.  Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients.

Authors:  T Tursz; A L Cesne; P Baldeyrou; E Gautier; P Opolon; C Schatz; A Pavirani; M Courtney; D Lamy; T Ragot; P Saulnier; A Andremont; R Monier; M Perricaudet; T Le Chevalier
Journal:  J Natl Cancer Inst       Date:  1996-12-18       Impact factor: 13.506

5.  Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes.

Authors:  J Gall; A Kass-Eisler; L Leinwand; E Falck-Pedersen
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

6.  Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit.

Authors:  P Yeh; J F Dedieu; C Orsini; E Vigne; P Denefle; M Perricaudet
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

7.  Expression of a foreign epitope on the surface of the adenovirus hexon.

Authors:  J Crompton; C I Toogood; N Wallis; R T Hay
Journal:  J Gen Virol       Date:  1994-01       Impact factor: 3.891

8.  The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 A resolution.

Authors:  F K Athappilly; R Murali; J J Rux; Z Cai; R M Burnett
Journal:  J Mol Biol       Date:  1994-09-30       Impact factor: 5.469

9.  Domains required for assembly of adenovirus type 2 fiber trimers.

Authors:  J S Hong; J A Engler
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  Chromogenic identification of genetic regulatory signals in Bacillus subtilis based on expression of a cloned Pseudomonas gene.

Authors:  M M Zukowski; D F Gaffney; D Speck; M Kauffmann; A Findeli; A Wisecup; J P Lecocq
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

View more
  45 in total

Review 1.  The promise and potential hazards of adenovirus gene therapy.

Authors:  L S Young; V Mautner
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

Review 2.  Gene transfer for cystic fibrosis.

Authors:  M J Welsh
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 3.  Vectors for gene therapy of cardiovascular disease.

Authors:  J F Dedieu; A Mahfoudi; A Le Roux; D Branellec
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

4.  Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.

Authors:  Di Yu; Chuan Jin; Justyna Leja; Nadim Majdalani; Berith Nilsson; Fredrik Eriksson; Magnus Essand
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

5.  Fiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity.

Authors:  John W Schoggins; Erik Falck-Pedersen
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

Review 6.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

7.  Characterization of a permissive epitope insertion site in adenovirus hexon.

Authors:  Michael J McConnell; Xavier Danthinne; Michael J Imperiale
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

8.  Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review).

Authors:  Lena J Gamble; Anton V Borovjagin; Qiana L Matthews
Journal:  Exp Ther Med       Date:  2010-03       Impact factor: 2.447

Review 9.  Current advances and future challenges in Adenoviral vector biology and targeting.

Authors:  Samuel K Campos; Michael A Barry
Journal:  Curr Gene Ther       Date:  2007-06       Impact factor: 4.391

10.  Intact microtubules support adenovirus and herpes simplex virus infections.

Authors:  Hélène Mabit; Michel Y Nakano; Ute Prank; Bianca Saam; Katinka Döhner; Beate Sodeik; Urs F Greber
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.